Clinical and Translational Oncology

, Volume 16, Issue 1, pp 18–28 | Cite as

Time trends of cancer incidence and mortality in Catalonia during 1993–2007

  • R. ClèriesEmail author
  • L. Esteban
  • J. Borràs
  • R. Marcos-Gragera
  • A. Freitas
  • M. Carulla
  • M. Buxó
  • A. Puigdefàbregas
  • Á. Izquierdo
  • R. Gispert
  • J. Galceran
  • J. Ribes
Special Article



To describe time trends of cancer in Catalonia, Spain, during the period 1993–2007.


Data have been provided by two population-based cancer registries, Girona and Tarragona, and the Catalan mortality registry. Cancer incidence in Catalonia has been estimated through modeling methods using data from these health structures.


During 2003–2007, there were 20,042 cancer cases and 9,842 deaths per year among men and 13,673 new cancer cases and 5,882 deaths among women. The most frequent incident cancers among men were prostate (N = 4,258), lung (N = 3,021), colorectal (N = 3,007) and bladder (N = 2,238), whereas among women they were breast (N = 3,907), colorectal (N = 2,088), corpus uteri (N = 734) and lung (N = 527). During 1993–2007, age-standardized incidence rates (ASIRs) rose 1.2 % per year among men [prostate (6.3 %), testis (5.7 %), kidney (2.9 %), liver (2.2 %) and colorectal (2.1 %)]. ASIRs decreased for stomach (−2.9 %), oral cavity and pharynx (−2.8 %), larynx (−2.7 %) and esophagus (−2 %). Among women, ASIRs only rose for lung (5.2 %), kidney (3.1 %), oral cavity and pharynx (2.6 %) and thyroid (1.6 %). ASIRs decreased for corpus uteri (−2.3 %), stomach (−1.7 %) and ovary (−1.6 %). Cancer mortality decreased −1.3 % per year among men and −2.1 % among women during the same period.


Among men, the decrease of incidence/mortality of tobacco-related tumors was related to a reduction of smoking prevalence. Among women, the stabilization of breast cancer incidence and the rise of lung cancer incidence are similar to that observed in most European regions. These results allow assessing the effectiveness of public health strategies and they pose new frontiers for cancer control in Catalonia.


Cancer Incidence Mortality Time trends Modeling 



This study was conducted within the framework of the Spanish Cancer Research Network (Red Temática de Investigación Cooperativa en Cáncer-RTICC) of the Carlos III Health Institute (Instituto de Salud Carlos III). Grants with reference number RD12/0036/0056; RD06/0020/0095; RD 06/020/0089. This study was also conducted within the Research Group–Catalan Cancer Registry [SGR 2009-2013] from the Agència de Gestió d’Ajuts Universitaris i de Recerca–AGAUR of the Catalan Government.

Conflict of interest

The authors declare that they have no conflict of interest related to the publication of this manuscript.

Supplementary material

12094_2013_1060_MOESM1_ESM.doc (112 kb)
Supplementary material 1 (DOC 112 kb)


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRefGoogle Scholar
  3. 3.
    Cleries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;10(31):978–87.CrossRefGoogle Scholar
  4. 4.
    Ribes J, Cleries R, Buxo M, Ameijide A, Valls J, Gispert R. Predictions of cancer incidence and mortality in Catalonia to 2015 by means of Bayesian models]. Med Clin (Barc). 2008;131(Suppl 1):32–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Sanchez MJ, Payer T, De Angelis R, Larranaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;05(Suppl 3:iii):30–6.Google Scholar
  6. 6.
    Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al, editors. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications; 2007.Google Scholar
  7. 7.
    World Health Organization. International Classification of Diseases, ninth revision. Geneva: WHO; 1977.Google Scholar
  8. 8.
    World Health Organization. International Statistical Classification of Diseases and Related Health problems, tenth revision. Geneva: WHO; 1992.Google Scholar
  9. 9.
    Esteban L, Cleries R, Galvez J, Pareja L, Escriba JM, Sanz X, et al. REGSTATTOOLS: freeware statistical tools for the analysis of disease population databases used in health and social studies. BMC Public Health. 2013;13(1):201.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: gLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRefGoogle Scholar
  12. 12.
    Malvezzi M, Bertuccio P, Levi F, la Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2013;24(3):792–800.PubMedCrossRefGoogle Scholar
  13. 13.
    Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Izquierdo A, Gispert R, Saladie F, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: breast cancer. Med Clin (Barc). 2008;131(Suppl 1):50–2.PubMedCrossRefGoogle Scholar
  15. 15.
    Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009;101(22):1584–91.PubMedCrossRefGoogle Scholar
  16. 16.
    Cleries R, Martinez JM, Moreno V, Yasui Y, Ribes J, Borras JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24(3):454–60.PubMedCrossRefGoogle Scholar
  17. 17.
    Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, la Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21(1):77–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Ribes J, Navarro M, Cleries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain: trends and projections for 1985–2019. Eur J Gastroenterol Hepatol. 2009;21(1):92–100.PubMedCrossRefGoogle Scholar
  19. 19.
    Borras JM, Pareja L, Peris M, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: colorectal cancer. Med Clin (Barc). 2008;131(Suppl 1):58–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Manchon-Walsh P, Borras JM, Espinas JA, Aliste L. Variability in the quality of rectal cancer care in public hospitals in Catalonia (Spain): clinical audit as a basis for action. Eur J Surg Oncol. 2011;37(4):325–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Malvezzi M, Bosetti C, Rosso T, Bertuccio P, Chatenoud L, Levi F, et al. Lung cancer mortality in European men: trends and predictions. Lung Cancer. 2013;80(2):138–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Borras JM, Pinol JL, Izquierdo A, Borras J. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Schiaffino A, Fernandez E, Kunst A, Borrell C, Garcia M, Borras JM, et al. Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000). Prev Med. 2007;45(2–3):226–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Lopez MJ, Fernandez E, Perez-Rios M, Martinez-Sanchez JM, Schiaffino A, Galan I, et al. Impact of the 2011 Spanish smoking ban in hospitality venues: indoor secondhand smoke exposure and influence of outdoor smoking. Nicotine Tob Res. 2013;15(5):992–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289–93.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMedGoogle Scholar
  27. 27.
    Marcos-Gragera R, Pollan M, Chirlaque MD, Guma J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3:iii):90–6.Google Scholar
  28. 28.
    Clèries R, Martínez JM, Escribà JM, Esteban L, Pareja L, Borràs JM, et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian approach. Cancer Epidemiology. 2010;34(3):244–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Ribes J, Pareja L, Esteban L, Cleries R. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: liver cancer. Med Clin (Barc). 2008;131(Suppl 1):83–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • R. Clèries
    • 1
    • 2
    Email author
  • L. Esteban
    • 1
  • J. Borràs
    • 3
    • 4
  • R. Marcos-Gragera
    • 5
    • 6
    • 7
  • A. Freitas
    • 8
  • M. Carulla
    • 3
  • M. Buxó
    • 5
    • 6
  • A. Puigdefàbregas
    • 8
  • Á. Izquierdo
    • 5
    • 6
  • R. Gispert
    • 8
  • J. Galceran
    • 3
  • J. Ribes
    • 1
    • 2
  1. 1.Registre de Càncer de Catalunya, Pla Director d’Oncologia (GENCAT). IDIBELLHospital Duran i ReynalsBarcelonaSpain
  2. 2.Departament de Ciències ClíniquesUniversitat de BarcelonaBarcelonaSpain
  3. 3.Registre de Càncer de TarragonaFundació Lliga Per a la Investigació i Prevenció del CàncerReusSpain
  4. 4.Departament de Medicina i CirurgiaUniversitat Rovira i VirgiliReusSpain
  5. 5.Unitat d’Epidemiología i Registre de Càncer en Girona (UERCG)Institut d’Investigació Biomèdica Girona Josep Trueta (IDIBGI)GironaSpain
  6. 6.Institut Català d’Oncologia (ICO)GironaSpain
  7. 7.Departament d’InfermeriaUniversitat de Girona (UdG)GironaSpain
  8. 8.Departament de SalutServei d’Informació i Estudis (GENCAT)BarcelonaSpain

Personalised recommendations